A New Method to Treat Hereditary Cerebellar Ataxia - Umbilical Cord Mesenchymal Stem Cells Transplantation (SCA)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
General Hospital of Chinese Armed Police Forces
ClinicalTrials.gov Identifier:
NCT01489267
First received: October 30, 2011
Last updated: June 18, 2012
Last verified: June 2012
  Purpose

Hereditary cerebellar ataxia is a type of autosomal dominant genetic disease, lesions mainly involving the cerebellum, but the spinal cord and cranial nerves may also be some involvement. A total of 20 molecularly diagnosed SCA1 patients divided in two groups. One group accepted for the treatment of stem cell transplantation,the other group will be the control. Purpose of this project to prove that allogeneic umbilical cord mesenchymal stem cells are applied to clinical safely, and in the treatment of hereditary cerebellar ataxia is valid.


Condition Intervention Phase
Hereditary Cerebellar Ataxia.
Other: stem cell transplantation
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cells Transplantation in Hereditary Cerebellar Ataxia Patients

Resource links provided by NLM:


Further study details as provided by General Hospital of Chinese Armed Police Forces:

Primary Outcome Measures:
  • blood test [ Time Frame: within one week before transplantation ] [ Designated as safety issue: Yes ]
    white blood cell、neutrophilic granulocyte、leukomonocyte;glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK);acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin;lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification

  • Nerve functional evaluation [ Time Frame: within one week before transplantation ] [ Designated as safety issue: Yes ]
    1. Timed-up-and-go test ,5 minutes down-and-up test
    2. ICARS score
    3. Modified Falls Efficacy Scale
    4. Berg balance assessment
    5. Tremor Rating Scale:

      • Part A - Tremor location/severity rating
      • Part B -Handwriting and drawings
      • Part C - Functional disabilities resulting from tremor
    6. Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)

  • blood test [ Time Frame: 1 month after transplantation ] [ Designated as safety issue: Yes ]
    white blood cell、neutrophilic granulocyte、leukomonocyte;glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK);acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin;lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification

  • blood test [ Time Frame: 3 months after transplantation ] [ Designated as safety issue: Yes ]
    white blood cell、neutrophilic granulocyte、leukomonocyte;glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK);acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin;lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification

  • blood test [ Time Frame: 6 months after transplantation ] [ Designated as safety issue: Yes ]
    white blood cell、neutrophilic granulocyte、leukomonocyte;glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK);acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin;lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification

  • blood test [ Time Frame: 12 months after transplantation ] [ Designated as safety issue: Yes ]
    white blood cell、neutrophilic granulocyte、leukomonocyte;glutamic pyruvic transaminase(GPT)、glutamic oxalacetic transaminase、lactate dehydrogenase(LDH)、;hydroxybutyrate dehydrogenase(HBDH)、phosphocreatine kinase(CK);acidum uricum(UA)、creatinine(Cr)、α1- microglobulin、β2- microglobulin;lymphotoxin(LCT). Tumor markers(AFP,CEA,CA125,CA15-3,CA19-9,CA72-4CY21-1,NSE) ,Lymphocytes classification

  • Nerve functional evaluation [ Time Frame: 1 month after transplantation ] [ Designated as safety issue: Yes ]
    1. Timed-up-and-go test ,5 minutes down-and-up test
    2. ICARS score
    3. Modified Falls Efficacy Scale
    4. Berg balance assessment
    5. Tremor Rating Scale:

      • Part A - Tremor location/severity rating
      • Part B -Handwriting and drawings
      • Part C - Functional disabilities resulting from tremor
    6. Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)

  • Nerve functional evaluation [ Time Frame: 3 months after transplantation ] [ Designated as safety issue: Yes ]
    1. Timed-up-and-go test ,5 minutes down-and-up test
    2. ICARS score
    3. Modified Falls Efficacy Scale
    4. Berg balance assessment
    5. Tremor Rating Scale:

      • Part A - Tremor location/severity rating
      • Part B -Handwriting and drawings
      • Part C - Functional disabilities resulting from tremor
    6. Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)

  • Nerve functional evaluation [ Time Frame: 6 months after transplantation ] [ Designated as safety issue: Yes ]
    1. Timed-up-and-go test ,5 minutes down-and-up test
    2. ICARS score
    3. Modified Falls Efficacy Scale
    4. Berg balance assessment
    5. Tremor Rating Scale:

      • Part A - Tremor location/severity rating
      • Part B -Handwriting and drawings
      • Part C - Functional disabilities resulting from tremor
    6. Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)

  • Nerve functional evaluation [ Time Frame: 12 months after transplantation ] [ Designated as safety issue: Yes ]
    1. Timed-up-and-go test ,5 minutes down-and-up test
    2. ICARS score
    3. Modified Falls Efficacy Scale
    4. Berg balance assessment
    5. Tremor Rating Scale:

      • Part A - Tremor location/severity rating
      • Part B -Handwriting and drawings
      • Part C - Functional disabilities resulting from tremor
    6. Questionnaires related to sleep, depression (Beck Depression Inventory) (BDI), alertness (Computerized Continuous Performing Tasks) and memory (Mini Mental State Examination)


Secondary Outcome Measures:
  • Urinal test [ Time Frame: within one week before transplantation ] [ Designated as safety issue: Yes ]
    proteinum、akaryocyte、α1- microglobulin、β2- microglobulin

  • Electrophysiology examination [ Time Frame: within one week before transplantation ] [ Designated as safety issue: Yes ]
    somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)

  • Urinal test [ Time Frame: 1 month after transplantation ] [ Designated as safety issue: Yes ]
    proteinum、akaryocyte、α1- microglobulin、β2- microglobulin

  • Urinal test [ Time Frame: 3 months after transplantation ] [ Designated as safety issue: Yes ]
    proteinum、akaryocyte、α1- microglobulin、β2- microglobulin

  • Urinal test [ Time Frame: 6 months after transplantation ] [ Designated as safety issue: Yes ]
    proteinum、akaryocyte、α1- microglobulin、β2- microglobulin

  • Urinal test [ Time Frame: 12 months after transplantation ] [ Designated as safety issue: Yes ]
    proteinum、akaryocyte、α1- microglobulin、β2- microglobulin

  • Electrophysiology examination [ Time Frame: 1 month after transplantation ] [ Designated as safety issue: Yes ]
    somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)

  • Electrophysiology examination [ Time Frame: 3 months after transplantation ] [ Designated as safety issue: Yes ]
    somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)

  • Electrophysiology examination [ Time Frame: 6 months after transplantation ] [ Designated as safety issue: Yes ]
    somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)

  • Electrophysiology examination [ Time Frame: 12 months after transplantation ] [ Designated as safety issue: Yes ]
    somatosensory evoked potential(SEP)、brain stem auditory evoked potential(BAEP)


Estimated Enrollment: 20
Study Start Date: December 2011
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control group
Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
Experimental: Stem cell transplantation
10 patients in the group accept stem cell transplantation.
Other: stem cell transplantation
The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10`7 cells).
Other Name: Cell therapy.

Detailed Description:

After admission the patients accepted transplantation would receive physical examination, blood and urine tests, electrocardiogram, electrophysiologic study;evaluation of SCA1 symptoms (balance, walking, dexterity, tremor, memory, mood and concentration),then stem cell therapy:after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The control only receive evaluation of SCA1 symptoms .

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18-65 years of age
  2. Molecularly diagnosed SCA1

Exclusion Criteria:

  1. Cognitively impaired individuals
  2. Schizophrenics
  3. Patients with severe kidney and liver disease, epilepsy, heart disease, pulmonary disease, cardiac arrhythmia, diabetes insipidus, leukemia and some other central neural disease (such as Parkinson disease, accidence of brain vascular et al)
  4. Age less than 18 years, age greater than 65 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489267

Locations
China
Yihua An
Beijing, China
Sponsors and Collaborators
General Hospital of Chinese Armed Police Forces
Investigators
Study Director: Yihua An, doctor director of neural stem cell transplantation department in general hospital of chinese armed police forces
  More Information

No publications provided

Responsible Party: General Hospital of Chinese Armed Police Forces
ClinicalTrials.gov Identifier: NCT01489267     History of Changes
Other Study ID Numbers: 20111031SCA, 20111031limin
Study First Received: October 30, 2011
Last Updated: June 18, 2012
Health Authority: Chinese:Food and Drug Administration

Keywords provided by General Hospital of Chinese Armed Police Forces:
cerebellar ataxia
hereditary disease
stem cell

Additional relevant MeSH terms:
Cerebellar Ataxia
Spinocerebellar Degenerations
Cerebellar Diseases
Ataxia
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Brain Diseases
Central Nervous System Diseases
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on August 28, 2014